Stockreport

Recursion: AI Hype Fizzles Amid Hard Clinical Truths [Seeking Alpha]

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF Follow Summary Recursion's REC-994 met safety and tolerability endpoints in the Phase 2 trial for CCM, but efficacy data were limited. Secondary endpoints showed [Read more]